The health department began to manage the treatment of prophylaxis of emicizumab to prevent episodes of bleeding in a 32 -year -old Thrissur woman suffering from congenital haemophilia A.
He is treated at Thrissur Government Medical College, after a detailed assessment of her condition and after advice by the medical team.
Hemophilia is a rare inherited bleeding disorder in which blood is not properly torn due to absence or low levels of clotting proteins known as factors. This can lead to long -term bleeding after injury or operations and repeated joint bleeding can lead to joint damage.
In nearly 80-85% of cases, bleeding is due to a lack of factor VIII, known as haemophilia A.
This disease is caused by mutations on chromosome X. Males are those who are commonly affected, while women are usually carriers, rarely women can be affected if there are mutations on both of their X chromosomes.
Thrissur woman suffered severe haemophilia with factor VIII less than one percent. Initially, she was treated as a patient with von Willebrand’s disease or VMD, in which bleeding disorder is the result of a defect of von Will’s blood factor, but a few blood tests later diagnosed her as a patient with haemophilia.
She had to remove her ovaries and uterus due to uncontrolled bleeding and was on hormonal treatment. After repeated episodes of bleeding and bleeding around the joints, which led to the joints, was under serious pain under repeated bleeding episodes
Pyrophylaxis strategy is considered to be the standard of care in haemophilia and because it reduces joint damage and frequency of bleeding episodes. Emicizumab is a non -actor therapy and is said to be a gamechanger when it comes to haemophilia A, as it can be submitted and the dosing plan is also more relaxed.
ASA SHAMA SCHEM
The state already gives Emicizumab without costs 500 odd patients under 18 years of age in the State under Ashadhara. This was useful in reducing bleeding of episodes and hospital visits in patients with haemophilia and changes were dramatic according to the health department
In his statement, Minister of Health Veen George claimed that Kerala was the first state to offer patients the prophylaxis of Emicizumab without costs. The state was also in advance in the design of reserved instructions for treatment for bleeding disorders in women.
Published – 15 September 2025 21:33
